Medline Q3 2026 adjusted EBITDA rises 12% to $960 million
MDLN•Medline’s third-quarter adjusted EBITDA rose 12% year over year to $960 million, including $81 million in net IEEPA tariff refund benefits. It raised FY26 organic sales growth guidance to 10%–10.5%, kept adjusted EBITDA guidance at $3.3 billion–$3.4 billion excluding tariff refund benefits, and authorized a share repurchase program of up to $1 billion.
1. Quarterly results and outlook
Medline’s Q3 2026 adjusted EBITDA rose 12% year over year to $960 million, including $81 million in net IEEPA tariff refund benefits. The company raised FY26 organic sales growth guidance to 10%–10.5%, from 9%–10%, while keeping adjusted EBITDA guidance at $3.3 billion–$3.4 billion, excluding tariff refund benefits. In October 2026, it authorized a share repurchase program of up to $1 billion.
